Search
Menu
Zurich Instruments AG - Boost Your Optics 1-24 LB

MDS Buying Molecular Devices for $615M

Facebook X LinkedIn Email
SUNNYVALE, Calif., and TORONTO, Jan. 29, 2007 -- Canada-based drug developer MDS Inc. today announced it will acquire Molecular Devices Corp., a bioanalytical measurement systems maker located in California, for $615 million in cash.

Under the agreement, which was unanimously approved by the boards of both companies, MDS will acquire all of Molecular Devices' common stock for $35.50 per share. MDS will spend $585 million to buy outstanding shares, plus another $30 million to buy outstanding stock options. MDS said it expected the transaction to be "modestly accretive" in 2007 and "significantly accretive in 2008 and beyond."

Headquartered in Sunnyvale, Molecular Devices supplies systems, reagents and software used by researchers to accelerate and improve drug discovery and other life sciences research. In the four quarters ending Sept. 2006, Molecular Devices reported revenues of $185 million.

In addition to making products that assist drug development, MDS provides medical isotopes for molecular imaging, radiotherapeutics and analytical instruments. It has 8800 employees in 28 countries.

MDS said it will create a new business unit that will combine Molecular Devices and MDS Sciex, to be led by MDS Sciex President Andy Boorn. The combined company will have more than 1100 employees, including over 250 scientists and engineers. The MDS Sciex and Molecular Devices brand names will continue to exist under the new business unit, MDS said, and MDS Sciex will continue to expand its mass spectrometry franchise by working with its joint venture partners Applied Biosystems and PerkinElmer.

"I am proud of what we have built at Molecular Devices and view this as a great combination," said Joe Keegan, president and CEO, Molecular Devices Corp. "We believe this acquisition is great news for our employees and our shareholders. By joining with MDS Sciex, the combined company will have a unique opportunity to bring innovative products to leading life sciences customers."

MDS said it expects to save $10 million to $12 million ($7 million in fiscal 2007) by consolidating the two companies. 

The transaction is subject to regulatory and other customary closing conditions and is expected to close in the second quarter of 2007.

For more information, visit: www.mdsinc.com
PI Physik Instrumente - Revolution In Photonics Align LW MR3/24

Published: January 2007
Glossary
closing
In morphological image processing, a series of dilations followed by the same number of erosions.
mass spectrometry
An instrumental technique that utilizes the mass-to-charge ratio of charged particles as recorded from a mass spectrometer in order to determine the mass of a particle as well as the chemical makeup, or elemental ionic composition of a given sample or molecule.
nano
An SI prefix meaning one billionth (10-9). Nano can also be used to indicate the study of atoms, molecules and other structures and particles on the nanometer scale. Nano-optics (also referred to as nanophotonics), for example, is the study of how light and light-matter interactions behave on the nanometer scale. See nanophotonics.
photonics
The technology of generating and harnessing light and other forms of radiant energy whose quantum unit is the photon. The science includes light emission, transmission, deflection, amplification and detection by optical components and instruments, lasers and other light sources, fiber optics, electro-optical instrumentation, related hardware and electronics, and sophisticated systems. The range of applications of photonics extends from energy generation to detection to communications and...
acquireApplied BiosystemsbioanalyticalBiophotonicsclosingdrug developerdrugsEmploymentlife sciencesmass spectrometryMDSMolecular Devicesmolecular imagingnanoNews & FeaturesPerkinElmerphotonicsspectroscopyTest & Measurementtransaction

We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.